Utah Medical Products Inc (UTMD) stock analysis
Close on Nov 11, 2026Market cap $232.51MP/E 22.3Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Mixed10 of 30 checks passed
Utah Medical Products passes 10 of the 30 checks behind our score; 13 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 3/6
- Growth
- 0/6
- Past performance
- 1/6
- Financial health
- 4/6
- Dividend
- 2/6
What stands out
Trading below fair value
The share price of $73.03 is below our fair value estimate of $76.45.
Return on capital over 10%
Return on invested capital was 23.9%, above the 10% that usually covers the cost of capital.
Low debt
Debt is 0.2% of shareholders' equity, under the 40% we consider low.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 6075% of total debt.
What to watch
Margin of safety under 20%
The price is 4.5% below fair value, less than the 20% cushion we look for.
Revenue growing under 10% a year
Revenue grew -9.7% a year over the last three fiscal years, short of the 10% we look for.
EPS growing under 10% a year
Diluted EPS grew -8.3% a year over the last three fiscal years.
P/E above its 5-year median
Utah Medical Products's P/E of 22.3 is above its own 5-year median of 18.6.
Valuation3/6
P/E above its 5-year median
Utah Medical Products's P/E of 22.3 is above its own 5-year median of 18.6.
P/E below the industry
Utah Medical Products's P/E of 22.3 is below the Surgical, Medical, and Dental Instruments and Supplies median of 27.7.
EV/EBITDA above its 5-year median
Utah Medical Products's EV/EBITDA of 14.1 is above its 5-year median of 11.6.
P/B below the industry
Utah Medical Products's price-to-book of 1.91 is below the Surgical, Medical, and Dental Instruments and Supplies median of 3.22.
Trading below fair value
The share price of $73.03 is below our fair value estimate of $76.45.
Margin of safety under 20%
The price is 4.5% below fair value, less than the 20% cushion we look for.
Growth0/6
Revenue growing under 10% a year
Revenue grew -9.7% a year over the last three fiscal years, short of the 10% we look for.
EPS growing under 10% a year
Diluted EPS grew -8.3% a year over the last three fiscal years.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growth against the industry
Needs revenue for this year and last.
Guidance issued
The latest outlook (total year 2026 consolidated sales decline, Oct 22, 2026) was issued for the first time, so it neither adds nor takes away points.
Gross margin trend
This company does not report gross profit.
Past performance1/6
Return on equity
Needs positive equity and five years of results.
Return on capital over 10%
Return on invested capital was 23.9%, above the 10% that usually covers the cost of capital.
Return on equity against the industry
Needs positive equity.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin against the industry
Needs revenue and net income.
Financial health4/6
Low debt
Debt is 0.2% of shareholders' equity, under the 40% we consider low.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 6075% of total debt.
Interest coverage
Interest expense is not reported separately.
Short-term assets cover short-term debts
Current assets are 48.62 times current liabilities.
Low bankruptcy risk
The Altman Z-score is 57.94; above 3 is the safe zone and below 1.8 the distress zone.
Dividend2/6
Pays a dividend
Utah Medical Products paid dividends worth 1.7% of the share price over the last twelve months.
Yield below Treasuries
The 1.7% yield is below the 4.4% on a 1-year Treasury.
Yield below the top quarter
The top quarter of US dividend payers yield 3.8% or more; Utah Medical Products yields 1.7%.
Dividend stability
Fewer than five years of dividend history.
Earnings cover
Needs dividends paid and net income.
Covered by free cash flow
Dividends take 34.4% of free cash flow.
Fair value
How we estimate itOur estimate per share
$76.45
The share price is 4% below this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/E | 23.1× | 18.6× | 27.7× | $75.71 | 40% |
| EV/EBITDA | 14.1× | 11.6× | 16.7× | $72.96 | 35% |
| P/B | 2.6× | 1.9× | 3.2× | $98.69 | 10% |
| Earnings power | 7.4% cost of equity | – | – | $71.73 | 15% |
| Fair value | $76.45 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 18.6
- Surgical, Medical, and Dental Instruments and Supplies median 27.7
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Medium risk
- Average value traded per day
- $2.77M
- Value traded per 1% price move
- $2.33M
Downside
Low risk
- Typical loss in a bad month
- 8.2%
- Volatility (annualized)
- 29%
- Sharpe ratio, 1 year
- 0.80
- Beta to the S&P 500 (5Y)
- 0.48
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
Operating margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -5.8% | -9.7% | -1.8% | -0.4% | |
| Gross profit | -8.9% | -11.9% | -2.9% | -0.9% | |
| Operating income | -16.1% | -16.8% | -3.6% | -3.1% | |
| EPS, diluted | -12.1% | -8.3% | +3.4% | +1.0% | |
| Free cash flow | -1.9% | -11.0% | -5.8% | +0.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | 11.41 | 16.42 | 37.62 | |
| Debt to equity | – | – | 0.00 | |
| Inventory turnover | 3.6× | 2.5× | 2.0× | |
| Capex to revenue | 8.4% | 2.0% | 1.0% | |
| Diluted shares | 4M | 4M | 3M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Utah Medical Products generated $94.15M from operations and spent $60.57M on capital expenditure, dividends and share buybacks. 4% of that went back into the business.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero$14.69M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income$14.69M vs –
- Less leverageLong-term debt to assets fell0.2% → 0.2%
- Better liquidityCurrent ratio rose25.64 → 37.62
- No dilutionShare count did not rise4M → 3M
- Gross margin improvedGross margin up on the prior year59.03% → 57.12%
- More efficientAsset turnover rose0.30 → 0.31
See a number that looks wrong?